Benzinga | Nov 2, 2021 10:23AM EDT

Arbutus Announces Late-Breaker Abstract Accepted For Presentation At AASLD - The Liver Meeting 2021

Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy at The American Association for the Study of Liver Diseases (AASLD) -- The Liver Meeting(r) 2021 -- The Digital Experience(tm), taking place from November 12-15, 2021.

Poster Presentation Details:

Title: Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy

Publication Number: LP20

Session Title: Late-Breaking Abstract Posters

Authors: MF Yuen, E Berliba, W Sukeepaisarnjaroen, P Tangkijvanich, A Leerapun, J Holmes, E Gane, A Jucov, EP Thi, M Sofia, H Sevinsky, T Eley, E Medvedeva, K Gray, D Antoniello, G Picchio, KD Sims, SI Strasser

Poster Session Schedule:

Friday, November 12 - 1:00 PM -- 3:00 PM ET

Saturday, November 13 - 8:00 AM -- 9:00 AM ET

Sunday, November 14 - 8:00 AM -- 9:00 AM ET

Monday, November 15 - 2:00 PM -- 3:00 PM ET

The poster will be available at the start of the The Liver Meeting(r) on November 12, 2021.

Key Findings:

* AB-729 repeat dosing is generally safe and well tolerated.

* Robust mean declines in HBsAg were sustained with repeat dosing of AB-729, with no meaningful differences observed to date between doses (60 mg or 90 mg) and/or dosing intervals (every 4, 8 or 12 weeks).

* HBsAg suppression at levels <100 IU/mL is maintained in some patients up to 20 weeks following the last dose of AB-729.